Compass Pathways plc (CMPS) — Compass Pathways reported fourth-quarter and full-year 2025 results, with 2025 R&D expense roughly flat at $118.4 million and G&A of $60.6 million.
The company said a February financing of about $150 million plus roughly $200 million from warrant exercises pushed its cash runway into 2028. Management pointed to an upcoming FDA meeting to confirm its NDA strategy for COMP360 psilocybin and reiterated a goal of being launch-ready by the end of 2026.
Source: businesswire.com
For the rest of that week's sector news, read our week in review.